Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127420561 | 12742056 | 1 | I | 20100615 | 20150710 | 20160914 | 20160914 | EXP | US-ROCHE-1666067 | ROCHE | 71.00 | YR | M | Y | 0.00000 | 20160914 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127420561 | 12742056 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | OVER 30-90 MINUTES ON DAY 1 (CYCLE 21 DAYS) | U | 125085 | 15 | MG/KG | SOLUTION FOR INFUSION | ||||||
| 127420561 | 12742056 | 2 | SS | LENALIDOMIDE | LENALIDOMIDE | 1 | Oral | ON DAYS 1-14 | U | 0 | 25 | MG | |||||||
| 127420561 | 12742056 | 3 | SS | DOCETAXEL. | DOCETAXEL | 1 | Intravenous (not otherwise specified) | OVER 60 MINUTES ON DAY 1 | U | 0 | 75 | MG/M**2 | |||||||
| 127420561 | 12742056 | 4 | SS | PREDNISONE. | PREDNISONE | 1 | Oral | U | 0 | 5 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127420561 | 12742056 | 1 | Prostate cancer |
| 127420561 | 12742056 | 2 | Prostate cancer |
| 127420561 | 12742056 | 3 | Prostate cancer |
| 127420561 | 12742056 | 4 | Prostate cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127420561 | 12742056 | HO |
| 127420561 | 12742056 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127420561 | 12742056 | Abdominal infection | |
| 127420561 | 12742056 | Alanine aminotransferase increased | |
| 127420561 | 12742056 | Aspartate aminotransferase increased | |
| 127420561 | 12742056 | Glucose tolerance impaired | |
| 127420561 | 12742056 | Hypertension | |
| 127420561 | 12742056 | Hypophosphataemia | |
| 127420561 | 12742056 | Hypotension | |
| 127420561 | 12742056 | Neutropenia | |
| 127420561 | 12742056 | Neutrophil count decreased | |
| 127420561 | 12742056 | Platelet count decreased | |
| 127420561 | 12742056 | Presyncope | |
| 127420561 | 12742056 | Syncope | |
| 127420561 | 12742056 | Thrombocytopenia | |
| 127420561 | 12742056 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127420561 | 12742056 | 1 | 20100429 | 0 | ||
| 127420561 | 12742056 | 2 | 20100429 | 0 | ||
| 127420561 | 12742056 | 3 | 20100429 | 0 | ||
| 127420561 | 12742056 | 4 | 20100429 | 0 |